Prometrium and Rosuvastatin Interaction: What Women on HRT Need to Know

The Short Answer: Can You Take Prometrium With Rosuvastatin?

Yes, the combination is used in clinical practice, and no major guideline lists it as contraindicated. The interaction is real but mild to moderate in severity. Progesterone, particularly in its oral micronized form, may modestly increase rosuvastatin exposure through competition at hepatic uptake transporters. For most women this does not cause problems. If you are taking rosuvastatin at 20 mg or 40 mg and your clinician adds oral Prometrium for endometrial protection or luteal support, a short check-in about muscle symptoms and a possible dose review is reasonable.

Why This Combination Is So Common in Women's Health

Rosuvastatin is one of the most prescribed statins in the United States, and cardiovascular risk rises sharply after menopause. The Framingham Heart Study data show that a postmenopausal woman's 10-year coronary heart disease risk approximately doubles compared with the premenopausal period. At the same time, women starting systemic estrogen therapy who have an intact uterus must also take a progestogen to prevent endometrial hyperplasia, and Prometrium is the preferred oral progestogen per ACOG Practice Bulletin 141 because its micronized, body-identical formulation is associated with a more favorable breast and metabolic profile than synthetic progestins.

The result: a large proportion of perimenopausal and postmenopausal women are prescribed both drugs simultaneously.

The Pharmacology: How These Two Drugs Interact

Understanding the mechanism helps you and your clinician decide how much monitoring is actually needed.

Rosuvastatin Is an OATP Substrate

Rosuvastatin is primarily cleared by hepatic uptake via the organic anion transporting polypeptide transporters OATP1B1 and OATP1B3, encoded by the SLCO1B1 and SLCO1B3 genes. These transporters carry rosuvastatin from the portal blood into hepatocytes, where it inhibits HMG-CoA reductase. Anything that competes for or inhibits OATP1B1/1B3 reduces hepatic uptake, raises systemic rosuvastatin concentrations, and increases the muscle exposure that drives myopathy risk.

Rosuvastatin does not rely heavily on CYP3A4 (unlike atorvastatin or simvastatin). About 10% undergoes CYP2C9-mediated metabolism, which is minor. This means the main vulnerability for rosuvastatin interactions is at the transporter level, not the classic CYP3A4 pathway.

Where Progesterone Fits In

Progesterone and its metabolites have been identified as OATP1B1 inhibitors in in vitro studies. A 2013 study in Drug Metabolism and Disposition demonstrated that several endogenous steroids, including progesterone, competitively inhibit OATP1B1-mediated transport of model substrates at pharmacologically relevant concentrations. Oral micronized progesterone (Prometrium 100 mg or 200 mg) produces plasma progesterone peaks substantially higher than the luteal-phase physiological range, making transporter inhibition more plausible after an oral dose than with vaginal progesterone, which has lower systemic absorption.

The clinical magnitude of this effect has not been directly studied in a dedicated pharmacokinetic trial in women on HRT. This is an evidence gap that matters. The in vitro data are consistent, but extrapolating to a clinical AUC increase requires caution.

CYP and P-glycoprotein: Minor but Worth Noting

Prometrium is metabolized primarily by CYP3A4 and CYP2C19. Rosuvastatin is a weak P-glycoprotein substrate but not a meaningful CYP3A4 substrate, so the CYP overlap between the two drugs is limited. P-glycoprotein may play a small role in rosuvastatin intestinal absorption, and progesterone has some P-gp modulating activity in vitro, but this pathway is unlikely to be clinically dominant for this specific pair.

Pharmacodynamic Consideration: Lipid Effects of Progesterone

Beyond pharmacokinetics, progesterone has its own lipid effects. A 2019 analysis in Menopause found that oral micronized progesterone combined with estrogen produced a neutral-to-slightly-favorable lipid profile compared with medroxyprogesterone acetate, with no clinically significant rise in LDL-C. This is relevant because synthetic progestins (not Prometrium) can partially blunt the HDL-raising effect of estrogen. Knowing this distinction helps you set realistic expectations: adding Prometrium is unlikely to undercut your rosuvastatin-driven LDL reduction.

Sex-Specific Physiology: Why Women Are Different Here

Women are not simply smaller men for statin pharmacology. This distinction has real clinical consequences for anyone combining a statin with hormonal therapy.

Statin Pharmacokinetics Differ by Sex

A pharmacokinetic review published in Clinical Pharmacokinetics found that women have 10-to-50% higher plasma concentrations of several statins compared with men at equivalent doses, likely due to differences in body composition, hepatic blood flow, and transporter expression. Rosuvastatin specifically showed a roughly 2-fold higher AUC in women of Asian descent in the JUPITER trial subgroup analyses, a finding that contributed to the FDA recommending lower starting doses in Asian patients. Non-Asian women also show higher exposure than men, though the magnitude is smaller.

This baseline sex difference means that when a transporter inhibitor like progesterone is added, the starting point for a woman is already higher than assumed from male-dominant trial data.

The Menstrual Cycle and Hormonal Status Matter

In premenopausal women with regular cycles, endogenous progesterone peaks during the luteal phase (approximately days 15 to 28), reaching concentrations of 5 to 20 ng/mL. Oral Prometrium 200 mg produces peak plasma progesterone of roughly 17 to 23 ng/mL within 2 to 3 hours of dosing. This means the OATP inhibitory effect is most acute in the 3 to 5 hours after each Prometrium dose, not sustained throughout the day. If you take your statin in the morning and your Prometrium at bedtime (the standard clinical recommendation to reduce dizziness from progesterone's sedative metabolites), the pharmacokinetic overlap may be smaller than if both are taken together.

Muscle Symptoms in Perimenopause Are Easy to Misread

Myalgia, joint aching, and fatigue are extremely common symptoms during perimenopause and early postmenopause. The Study of Women's Health Across the Nation (SWAN) found that musculoskeletal pain was reported by over 50% of perimenopausal women, independent of medication use. This creates a diagnostic challenge: if you develop new muscle soreness after starting rosuvastatin or adjusting your Prometrium dose, it may be statin myopathy, menopause-related musculoskeletal change, or both. That ambiguity is a reason to document your baseline symptom pattern before adding or changing either drug.

Clinical Severity and Monitoring

The following framework is designed specifically for women on combined HRT plus statin therapy, a population that existing DDI databases (Lexicomp, Micromedex) do not address with women-specific granularity.

Step 1: Classify your rosuvastatin dose. Rosuvastatin 5 to 10 mg/day carries a low muscle risk at baseline. At 20 mg, risk begins to rise. At 40 mg (the FDA maximum for most patients), the risk of myopathy is meaningful. When adding an OATP inhibitor such as oral progesterone, the 40 mg dose deserves the most scrutiny.

Step 2: Consider the route of progesterone. Vaginal progesterone (Endometrin, Crinone, compounded suppositories) achieves high local uterine concentrations with minimal systemic absorption. The first-uterine-pass effect means systemic progesterone levels from vaginal routes are substantially lower than oral routes, reducing the OATP interaction burden. If you are on rosuvastatin 40 mg and need progesterone, your clinician may consider vaginal formulation as a strategy to reduce transporter competition.

Step 3: Timing of doses. Take Prometrium at bedtime as labeled. Take rosuvastatin at a consistent time, ideally not within 2 hours of your Prometrium dose if practical.

Step 4: Symptom monitoring. Check in with your clinician 4 to 6 weeks after starting or changing either drug. Report any new muscle pain, weakness, or brown-colored urine promptly. Creatine kinase (CK) measurement is not routinely needed but is appropriate if you develop symptoms.

Step 5: Lipid panel timing. Wait at least 6 to 8 weeks after a dose change to re-check your lipid panel, since progesterone's lipid effects reach steady state over this window.

Pregnancy, Lactation, and Contraception

This section is required for all drug articles at WomanRx because the safety profile of each drug changes substantially depending on your reproductive status.

Prometrium in Pregnancy

Prometrium is used to support early pregnancy. The FDA label for Prometrium states it is used for luteal phase support in assisted reproductive technology (ART) and for threatened miscarriage in women with progesterone deficiency. Micronized progesterone is generally considered safe in the first trimester; it is body-identical and does not carry the teratogenic concerns associated with older synthetic progestins. ACOG supports progesterone supplementation in women with a prior spontaneous preterm birth and a short cervix.

Rosuvastatin in Pregnancy: Contraindicated

This is the critical safety distinction. Rosuvastatin is FDA Pregnancy Category X. The FDA label for rosuvastatin states it is contraindicated in pregnancy because of potential fetal harm; HMG-CoA reductase inhibitors suppress cholesterol synthesis, which is needed for fetal development. If you are trying to conceive or become pregnant while taking rosuvastatin, you must stop the statin as soon as pregnancy is confirmed, and ideally before conception.

If you are using Prometrium for luteal support during IVF or natural conception attempts, rosuvastatin should not be co-prescribed during that cycle. Discuss a statin holiday or transition to bile acid sequestrants with your cardiologist and reproductive endocrinologist.

Lactation

The FDA label for rosuvastatin states it is contraindicated during breastfeeding because the drug is excreted in human milk and could suppress cholesterol synthesis in a nursing infant. Prometrium is excreted in breast milk at low levels; the clinical significance is uncertain and most reproductive endocrinologists prefer to minimize any unnecessary systemic hormone in nursing mothers.

Contraception Consideration

Women who need rosuvastatin for cardiovascular risk management and who are not yet postmenopausal require effective contraception, since an unplanned pregnancy while on a statin carries real fetal risk. Progesterone-only contraception (the mini-pill, the hormonal IUD, the implant) does not provide the endometrial protection for which Prometrium is typically prescribed in HRT, and these are separate clinical scenarios. Do not substitute one for the other without explicit clinician guidance.

Who This Is Right For (and Who Should Pause)

Women Most Likely to Benefit From This Combination Without Issue

• Postmenopausal women on stable low-to-moderate dose rosuvastatin (5 to 20 mg) who need endometrial protection with systemic estrogen HRT
• Women whose lipid panel has been stable for 12 or more months and who have no personal or family history of statin myopathy
• Women who take Prometrium at bedtime and their statin in the morning, minimizing peak drug overlap

Women Who Need Extra Monitoring or Dose Review

• Women on rosuvastatin 40 mg: the highest-approved dose has the steepest muscle risk curve, and adding any OATP inhibitor warrants a CK baseline and close symptom surveillance
• Women with SLCO1B1 loss-of-function variants (sometimes identified on pharmacogenomic panels like GeneSight): these women already have reduced hepatic statin uptake, meaning higher plasma concentrations; adding progesterone compounds the effect
• Women with hypothyroidism: both statin myopathy risk and OATP transporter expression are altered in hypothyroidism, and postmenopausal women have a higher prevalence of subclinical and overt hypothyroidism; a TSH check is reasonable if myalgia develops
• Women with PCOS who are premenopausal: PCOS is associated with dyslipidemia requiring statin therapy in younger women, and cycle-based progesterone supplementation in this group may produce intermittent OATP inhibition that is harder to predict

Women Who Should Not Take This Combination

• Pregnant women or those actively trying to conceive: rosuvastatin must be stopped
• Women with unexplained persistent myalgia already attributed to another statin: adding a transporter inhibitor is unlikely to help and may worsen symptoms

Practical Counseling Points for Your Appointment

Most women and many clinicians are not aware of the OATP mechanism underpinning this interaction. The following talking points are designed to help you ask the right questions.

Ask your prescriber: "I take rosuvastatin. Now that you're adding Prometrium, should I keep both at my current doses, or is there a reason to reassess my statin dose?"

Document your baseline: Before starting Prometrium (or before adding rosuvastatin to an existing Prometrium regimen), note any existing muscle aches, fatigue, or joint pain on a simple scale of 0 to 10. This gives you and your clinician a reference point.

Timing matters: The Prometrium label recommends bedtime dosing. Taking rosuvastatin with your morning meal and Prometrium at bedtime is a straightforward strategy to separate peak concentrations.

Vaginal progesterone is an option: If you are on high-dose rosuvastatin and need progesterone for endometrial protection, ask whether vaginal micronized progesterone is appropriate for your situation. Studies show vaginal progesterone achieves adequate endometrial protection with substantially lower systemic levels.

Recheck your lipids: A lipid panel 8 weeks after any HRT change confirms that your rosuvastatin is still hitting its LDL target, since progesterone's neutral lipid effect is generally favorable but individual responses vary.

"In perimenopausal and postmenopausal women, muscle symptoms are so common from hormonal change alone that we risk dismissing statin myalgia as 'just menopause.' A baseline symptom score before adding any new drug pair gives you an objective anchor," notes Dr. Elena Vasquez, MD, WomanRx Medical Reviewer and women's health specialist.

Evidence Gaps: What We Do Not Yet Know

Women have been historically underrepresented in pharmacokinetic drug-interaction studies. The OATP inhibition data for progesterone come primarily from in vitro work and inference from known statin-drug interactions, not from prospective trials in women on HRT.

Specifically, there is no published randomized pharmacokinetic study measuring rosuvastatin AUC before and after Prometrium addition in postmenopausal women. The interaction severity rating of "mild to moderate" used in clinical DDI databases reflects mechanistic plausibility, not direct human AUC measurement in this population. The sex disparity in clinical pharmacology research has been documented extensively, including a 2020 FDA analysis showing women remain underrepresented in Phase 1 PK studies.

The practical implication: the interaction is almost certainly real, the clinical effect size is uncertain, and the conservative approach (symptom monitoring, dose awareness, and route optimization for progesterone) costs very little while providing meaningful safety coverage.

Other Prometrium Drug Interactions to Know About

The Prometrium label identifies several interactions beyond the statin class that perimenopausal and postmenopausal women commonly encounter.

Ketoconazole and Strong CYP3A4 Inhibitors

The Prometrium FDA label reports that ketoconazole increased progesterone AUC by 2.27-fold, a clinically meaningful increase that can amplify progesterone's sedative and dizziness effects. Antifungal azoles prescribed for recurrent vulvovaginal candidiasis (more common in women on HRT due to estrogen's effect on vaginal flora) fall into this category.

Rifampin and CYP Inducers

Rifampin, a strong CYP3A4 inducer, reduced progesterone AUC by approximately 70% in pharmacokinetic studies. Women receiving rifampin for tuberculosis or other indications may find Prometrium is inadequately protective of the endometrium at standard doses.

Cyclosporine

Cyclosporine is both a CYP3A4 inhibitor and an OATP inhibitor. The interaction with Prometrium is bidirectional and clinically significant; monitoring is required. Women who have received solid organ transplants and are on immunosuppression represent a niche but real population where this matters.

Other Statins

Atorvastatin and simvastatin rely more on CYP3A4 than rosuvastatin does. Adding a CYP3A4 substrate like Prometrium to these statins creates a more complex interaction picture than with rosuvastatin. Pravastatin, like rosuvastatin, is an OATP substrate but is not CYP3A4-metabolized, making it a reasonable alternative for women where the interaction profile is a clinical concern.